Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Qatar signs deal to buy Moderna COVID-19 vaccine

10/25/2020 | 09:56am EST
Moderna Therapeutics seen during COVID-19 in Massachusetts

DUBAI (Reuters) - Qatar has signed an agreement with drugmaker Moderna Inc to buy its potential COVID-19 vaccine as soon as it is approved and released for global use, state news agency QNA quoted a health official as saying on Sunday.

There are no internationally approved vaccines yet, but several are in advanced trials, including from Pfizer Inc, Johnson & Johnson and Moderna.

"Negotiating early and securing a number of agreements enhances our chances of getting sufficient quantities of the vaccine early," said Abdullatif al-Khal, chair of a national COVID-19 health group and head of infectious diseases at Hamad Medical Corporation.

He did not say how many doses Doha was requesting. Earlier this month, al-Khal said Qatar signed an agreement with Pfizer and BioNTech to supply Qatar with their vaccines.

Moderna said last month it was on track to produce 20 million doses of its vaccine by the end of the year, while maintaining its goal of readying 500 million to 1 billion doses in 2021.

The American group is also working with Swiss group Lonza AG to scale up the manufacturing and production of its potential COVID-19 vaccine to supply markets outside the United States.

(Reporting by Yousef Saba; Writing by Ghaida Ghantous; Editing by Andrew Heavens)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -8.23% 114.01 Delayed Quote.266.71%
MODERNA, INC. -7.68% 141.01 Delayed Quote.680.88%
PFIZER, INC. 2.87% 39.41 Delayed Quote.3.21%
All news about MODERNA, INC.
05:59pU.S. Panel Recommends Giving First Covid Vaccines to Health Workers, Nursing ..
DJ
05:27pGlobal equity markets jump, bonds dip, on hopes of vaccine-led recovery
RE
05:24pPFIZER : Pushed to rush, FDA head says feds will get vaccine 'right'
AQ
05:20pBrazil sees one-dose, unfrozen vaccine as ideal for COVID-19 -official
RE
04:37pHealth Care Up As Hospital Chains Rebound -- Health Care Roundup
DJ
04:23pGlobal equity markets jump, bonds dip, on hopes of vaccine-led recovery
RE
04:19pS&P 500, Nasdaq end at record highs on vaccine optimism
RE
02:51pS&P 500, Nasdaq hit records on vaccine optimism
RE
01:01pTrump to meet COVID-19 vaccine makers, distributors next week - Stat News
RE
12:12pEUROPE : European shares rise on vaccine hopes; Brexit talks eyed
RE
More news
Financials (USD)
Sales 2020 449 M - -
Net income 2020 -673 M - -
Net cash 2020 2 584 M - -
P/E ratio 2020 -95,6x
Yield 2020 -
Capitalization 55 799 M 55 799 M -
EV / Sales 2020 119x
EV / Sales 2021 7,40x
Nbr of Employees 1 100
Free-Float 90,0%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 114,35 $
Last Close Price 141,01 $
Spread / Highest target 31,2%
Spread / Average Target -18,9%
Spread / Lowest Target -57,4%
EPS Revisions
Managers
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.680.88%60 441
LONZA GROUP AG61.27%46 692
CELLTRION, INC.87.85%41 055
IQVIA HOLDINGS INC.9.37%32 400
SEAGEN INC.49.05%30 708
IMMUNOMEDICS, INC.315.22%20 324